Southern Asia: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Southern Asia

The South Asian prophylactic medicaments containing insulin market amounted to $X in 2022, approximately mirroring the previous year. In general, consumption showed a remarkable increase. Over the period under review, the market reached the maximum level at $X in 2020; however, from 2021 to 2022, consumption stood at a somewhat lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Southern Asia

In value terms, prophylactic medicaments containing insulin production expanded slightly to $X in 2022 estimated in export price. Over the period under review, production recorded a buoyant increase. The most prominent rate of growth was recorded in 2019 with an increase of 24%. The level of production peaked at $X in 2020; however, from 2021 to 2022, production remained at a lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports in Southern Asia

In 2022, overseas shipments of medicaments containing insulin but not antibiotics in measured doses were finally on the rise to reach X tons for the first time since 2013, thus ending a eight-year declining trend. Over the period under review, exports, however, recorded a drastic downturn. The most prominent rate of growth was recorded in 2013 when exports increased by 82% against the previous year. As a result, the exports reached the peak of X tons. From 2014 to 2022, the growth of the exports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin exports expanded rapidly to $X in 2022. In general, exports, however, continue to indicate a slight curtailment. The most prominent rate of growth was recorded in 2013 with an increase of 45% against the previous year. As a result, the exports reached the peak of $X. From 2014 to 2022, the growth of the exports remained at a lower figure.

Exports by Country

India prevails in exports structure, amounting to X tons, which was near 97% of total exports in 2022. Pakistan (X tons) held a relatively small share of total exports.

From 2012 to 2022, average annual rates of growth with regard to prophylactic medicaments containing insulin exports from India stood at -6.4%. At the same time, Pakistan (+20.1%) displayed positive paces of growth. Moreover, Pakistan emerged as the fastest-growing exporter exported in Southern Asia, with a CAGR of +20.1% from 2012-2022. From 2012 to 2022, the share of Pakistan increased by +2.3 percentage points.

In value terms, India ($X) remains the largest prophylactic medicaments containing insulin supplier in Southern Asia, comprising 95% of total exports. The second position in the ranking was taken by Pakistan ($X), with a 4.9% share of total exports.

From 2012 to 2022, the average annual rate of growth in terms of value in India amounted to -1.6%.

Export Prices by Country

In 2022, the export price in Southern Asia amounted to $X per ton, reducing by -11.1% against the previous year. Over the period under review, the export price, however, showed a resilient increase. The pace of growth appeared the most rapid in 2019 when the export price increased by 52% against the previous year. Over the period under review, the export prices hit record highs at $X per ton in 2021, and then reduced in the following year.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was Pakistan ($X per ton), while India totaled $X per ton.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by India (+5.2%).

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports in Southern Asia

In 2022, overseas purchases of medicaments containing insulin but not antibiotics in measured doses decreased by -17.6% to X tons, falling for the second consecutive year after seven years of growth. In general, imports, however, enjoyed a temperate expansion. The most prominent rate of growth was recorded in 2019 with an increase of 26% against the previous year. Over the period under review, imports attained the maximum at X tons in 2020; however, from 2021 to 2022, imports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin imports shrank to $X in 2022. Total imports indicated strong growth from 2012 to 2022: its value increased at an average annual rate of +5.6% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. The pace of growth was the most pronounced in 2014 when imports increased by 15%. The level of import peaked at $X in 2021, and then declined slightly in the following year.

Imports by Country

In 2022, Pakistan (X tons) was the key importer of medicaments containing insulin but not antibiotics in measured doses, mixing up 66% of total imports. India (X tons) held a 21% share (based on physical terms) of total imports, which put it in second place, followed by Bangladesh (6.2%) and Nepal (5%). Sri Lanka (X tons) held a little share of total imports.

Imports into Pakistan increased at an average annual rate of +2.1% from 2012 to 2022. At the same time, India (+34.1%), Sri Lanka (+19.1%) and Nepal (+18.3%) displayed positive paces of growth. Moreover, India emerged as the fastest-growing importer imported in Southern Asia, with a CAGR of +34.1% from 2012-2022. By contrast, Bangladesh (-4.6%) illustrated a downward trend over the same period. From 2012 to 2022, the share of India, Nepal and Sri Lanka increased by +19, +3.6 and +1.7 percentage points, respectively.

In value terms, India ($X) constitutes the largest market for imported medicaments containing insulin but not antibiotics in measured doses in Southern Asia, comprising 67% of total imports. The second position in the ranking was taken by Pakistan ($X), with a 21% share of total imports. It was followed by Bangladesh, with a 6.7% share.

From 2012 to 2022, the average annual rate of growth in terms of value in India stood at +4.2%. In the other countries, the average annual rates were as follows: Pakistan (+17.0% per year) and Bangladesh (-1.7% per year).

Import Prices by Country

In 2022, the import price in Southern Asia amounted to $X per ton, rising by 17% against the previous year. Over the period from 2012 to 2022, it increased at an average annual rate of +1.3%. The growth pace was the most rapid in 2021 an increase of 18% against the previous year. Over the period under review, import prices attained the peak figure in 2022 and is expected to retain growth in the immediate term.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was India ($X per ton), while Pakistan ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Pakistan (+14.6%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :